XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1

Derivative Financial Instruments - Warrants

12 Months Ended

Dec. 31, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments - Warrants

Derivative Financial Instruments — Warrants

    Certain warrants issued in connection with the Company’s equity financings are accounted for as derivative liabilities. Accordingly, the warrants are remeasured at each balance sheet date based on their estimated fair value using the Black-Scholes option pricing model. These warrants expired during the first quarter of 2023. Changes in fair value are recorded within Company’s statements of operations.

The assumptions used to determine the fair value of the warrants using the Black-Scholes option pricing model were:

									As of December 31, 2022
Fair value of Cardiff Oncology common stock									$1.40
Expected warrant term									0.1 years
Risk-free interest rate									4.12		%
Expected volatility of Cardiff Oncology common stock									54		%
Dividend yield									0		%

Expected volatility is based on the historical volatility of Cardiff Oncology’s common stock. The warrants have a transferability provision and based on guidance for instruments issued with such a provision, Cardiff Oncology used the remaining contractual term as the expected term of the warrants. The risk-free interest rate is based on the U.S. Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date.

The following table sets forth the components of changes in the Company’s derivative financial instruments—warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.

(in thousands, except for number of warrants)
Date						Description						Number of Warrants						Derivative Instrument Liability
December 31, 2021						Balance of derivative financial instruments—warrants liability						64,496						$	285
						Change in fair value of derivative financial instruments—warrants during the year recognized as a gain in the statement of operations						—						(285)
December 31, 2022						Balance of derivative financial instruments—warrants liability						64,496						—
						Expiration of Derivative Financial Instruments						(64,496)						—
						Change in fair value of derivative financial instruments—warrants during the year recognized as a loss in the statement of operations						—						—
December 31, 2023						Balance of derivative financial instruments—warrants liability						—						$	—

X

- References

No definition available.

+ Details

Name:	us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-5

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480434/815-10-50-5C

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 815
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//815/tableOfContent

+ Details

Name:	us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration